glp-1 receptor agonist side effects Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, effects, and risks Clinical Recommendations to Manage Gastrointestinal

HF The prevalence of HF has become an increasing concern for patients with T2DM

Zhang QY, et al

Role of glucagon-like peptide-1 receptor agonists in people with infertility and pregnancy

Scientists from the WHO recently wrote: The approval of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of obesity creates potential for a transformation of the whole health system that could halt and reverse the global obesity pandemic through prevention and effective integrated management. Growing crisis South Africa is grappling with dual diabetes and obesity epidemics, on top of the HIV and TB epidemics, but is not responding effectively, resulting in high obesity and diabetes-related deaths

Importantly, GLP1 receptor agonists offer the potential to serve as a glidepath for individuals who have struggled to get started with behavioral modification due to preexisting overweight or obesity